Cost-of-illness of scleroderma: The case for rare diseases

https://doi.org/10.1016/S0049-0172(97)80008-XGet rights and content

Abstract

Objective:

To determine the societal costs of scleroderma (SSc), a rare chronicconnective tissue disease that affects approximately 98,000 Americans. Lack of reliable national databases limit rare disease cost studies, and this study suggests methods of using multiple data sources to assess the costs of rare diseases.

Methods:

Primary and secondary data sources were used to calculate directand indirect costs of SSc, including discounted lifetime mortality and morbidity costs. A prevalence-based, human capital approach was used. Sensitivity analyses were used to vary parameters that are uncertain, such as prevalence, mortality, and labor costs.

Results:

Annual direct and indirect costs of SSc in the United States are $1.5 billion. Morbidity represents the major cost burden, with costs of $819 million (56%) of total costs. The current value of lifetime earnings lost was $179 million (12%) or $300,000 per death. Direct costs were $462 million (32%) or $4,731 per person annually, indicating that costs are spread over the long disease duration.

Conclusions:

This study provides one model for the assessment of rare diseasecosts. Triangulation of data sources and sensitivity analyses are important for determining the costs of rare diseases. The high cost of SSc, despite its low prevalence, suggests that the burden of rare chronic diseases can be high. The high morbidity costs reflect the young age of onset of the disease as well as the need for treatments to decrease morbidity costs. Local shared databases and national surveys are needed to improve cost estimates of rare diseases.

References (37)

  • SteenV.D.

    Epidemiology of rheumatic disease: systemic sclerosis

    Rheum Dis Clin North Am

    (1990)
  • HartunianN.S. et al.

    The incidence and economic costs of cancer, motor vehicle injuries, coronary heart disease, and stroke: a comparative analysis

    AJPH

    (1980)
  • RiceD.P. et al.
  • MedsgerT.A.

    Epidemiology of systemic sclerosis

    Clin Dermatol

    (1993)
  • BruckdorferK.R. et al.

    Increased susceptibility to oxidation of low-density lipoproteins isolated from patients with systemic sclerosis

    Arthritis Rheum

    (1995)
  • WhiteB. et al.

    Guidelines for clinical trials in systemic sclerosis (scleroderma)

    Arthritis Rheum

    (1995)
  • SteenV.D. et al.

    Epidemiology and natural history of systemic sclerosis

    Rheum Dis Clin North Am

    (1990)
  • Abu-ShakraM. et al.

    Mortality in systemic sclerosis: a comparison with the general population

    J Rheumatol

    (1995)
  • AltmanR.D. et al.

    Predictors of survival in systemic sclerosis (scleroderma)

    Arthritis Rheum

    (1991)
  • HochbergM.C. et al.

    Mortality from systemic sclerosis (scleroderma) in the United States, 1969–1977

  • SteenV.D. et al.

    Severe restrictive lung disease in systemic sclerosis

    Arthritis Rheum

    (1994)
  • ValentineG.

    Classification of systemic sclerosis

    Clin Dermatol

    (1994)
  • FriesJ.F. et al.

    Criteria for rheumatic disease

    Arthritis Rheum

    (1994)
  • SillmanA. et al.

    Epidemiology of rheumatic disease: scleroderma

    (1993)
  • HodgsonT.A. et al.

    Cost-of-illness methodology: a guide to current practices and procedures

    Milbank Mem Fund Q

    (1982)
  • MedsgarT.A.

    Epidemiology of systemic sclerosis

    Clin Dermatol

    (1994)
  • MaricqH.R. et al.

    Prevalence of scleroderma spectrum disorders in the general population of S. Carolina

    Arthritis Rheum

    (1989)
  • MichetC.J. et al.

    Epidemiology of systemic lupus erythematosus and other connective tissue diseases in Rochester, Minnesota, 1950 through 1979

    • Cited by (43)

    • Health Care Utilization: What Is the Cost of Caring for Scleroderma?

      2023, Rheumatic Disease Clinics of North America

    • Employment outcomes in systemic sclerosis

      2021, Best Practice and Research: Clinical Rheumatology
      Citation Excerpt :

      Definitions of indirect costs varied from the study and included hours lost from productivity, early retirement, or the duration of short-term or long-term disability leaves. Of the six studies that evaluated both direct and indirect total costs, four studies reported higher total indirect costs relative to total direct costs [19,49–51]. Total direct costs include direct healthcare costs (this includes drugs, hospitalizations, emergency room visits, and visits to medical specialists), direct non-healthcare formal costs (number of hours of care by professional caregivers), and direct non-healthcare informal costs (number of hours of care by caregivers).

    • Socio-economic burden of rare diseases: A systematic review of cost of illness evidence

      2015, Health Policy
      Citation Excerpt :

      Mean annual indirect costs were €10,275/patient (CA$13,415 in 2007) in Canada, of which 40% was attributed to lost productivity from paid labour and 60% from unpaid labour [30]. American indirect costs were differentiated as mortality losses €2,038/patient (US$1,835 in 1994) and morbidity losses of €9,319/patient (US$8,392 in 1994) for a total of €11,357/patient [103]. Recent estimates of direct medical cost of scleroderma are €4,128 in Hungary (€3,300 in 2006), of which hospitalisation was the largest component (82%) and drugs accounted for 12% [105].

    • Socioeconomic costs of digital ulcer treatment among patients with systemic sclerosis: A pilot observational study in Italy

      2010, Revue du Rhumatisme (Edition Francaise)

    • The social costs of digital ulcer management in sclerodema patients: An observational Italian pilot study

      2010, Joint Bone Spine

    • The autoimmunologist: geoepidemiology, a new center of gravity, and prime time for autoimmunity

      2008, Journal of Autoimmunity
    View all citing articles on Scopus

    Supported by an unrestricted grant from Connetics Corp,Palo Alto, CA.

    View full text
    Copyright © 1997 Published by Elsevier Inc.